These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32935744)

  • 21. Current allocation policy is favorable for patients with hepatocellular carcinoma waiting for liver transplantation.
    Ferre-Aracil C; Lledó JL; Aguilera L; Garcia-Paredes A; Rodríguez-Santiago E; Graus J; García-González M; Nuño J; López-Buenadicha A; López-Hervás P; Rodríguez-Gandía M; Gea F; Albillos A
    Dig Liver Dis; 2018 Dec; 50(12):1345-1350. PubMed ID: 29807872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change.
    Ishaque T; Massie AB; Bowring MG; Haugen CE; Ruck JM; Halpern SE; Waldram MM; Henderson ML; Garonzik Wang JM; Cameron AM; Philosophe B; Ottmann S; Rositch AF; Segev DL
    Am J Transplant; 2019 Feb; 19(2):564-572. PubMed ID: 30312530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. End-stage liver disease candidates at the highest model for end-stage liver disease scores have higher wait-list mortality than status-1A candidates.
    Sharma P; Schaubel DE; Gong Q; Guidinger M; Merion RM
    Hepatology; 2012 Jan; 55(1):192-8. PubMed ID: 21898487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
    Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
    Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An Outcome-Based Approach to Assign MELD Exception Points for Patients With Hepatocellular Cancer.
    Kensinger CD; Feurer ID; Karp SJ
    Transplantation; 2017 Sep; 101(9):2056-2061. PubMed ID: 28471871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The MELD system and liver transplant waiting-list mortality in developing countries: lessons learned from São Paulo, Brazil.
    Salvalaggio P; Afonso RC; Pereira LA; Ferraz-Neto BH
    Einstein (Sao Paulo); 2012; 10(3):278-85. PubMed ID: 23386004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the Share 35 Rule on Waitlist and Liver Transplantation Outcomes for Patients with Hepatocellular Carcinoma.
    Croome KP; Lee DD; Harnois D; Taner CB
    PLoS One; 2017; 12(1):e0170673. PubMed ID: 28122003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential Impact of Age Among Liver Transplant Candidates With and Without Hepatocellular Carcinoma.
    Cullaro G; Rubin JB; Mehta N; Lai JC
    Liver Transpl; 2020 Mar; 26(3):349-358. PubMed ID: 31610089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
    Berry K; Ioannou GN
    Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the Liver Transplant Waiting List in Our Center.
    Emek E; Yesim Kara Z; Demircan FH; Serin A; Yazici P; Sahin T; Tokat Y; Bozkurt B
    Transplant Proc; 2019 Sep; 51(7):2413-2415. PubMed ID: 31474297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous Risk Score Predicts Waitlist and Post-transplant Outcomes in Hepatocellular Carcinoma Despite Exception Changes.
    Akabane M; McVey JC; Firl DJ; Kwong AJ; Melcher ML; Kim WR; Sasaki K
    Clin Gastroenterol Hepatol; 2024 Oct; 22(10):2044-2052.e4. PubMed ID: 38908731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis.
    Kulik L; Heimbach JK; Zaiem F; Almasri J; Prokop LJ; Wang Z; Murad MH; Mohammed K
    Hepatology; 2018 Jan; 67(1):381-400. PubMed ID: 28859222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver transplantation in the MELD era: a single-center experience.
    Sachdev M; Hernandez JL; Sharma P; Douglas DD; Byrne T; Harrison ME; Mulligan D; Moss A; Reddy K; Vargas HE; Rakela J; Balan V
    Dig Dis Sci; 2006 Jun; 51(6):1070-8. PubMed ID: 16865573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. List and liver transplant survival according to waiting time in patients with hepatocellular carcinoma.
    Salvalaggio PR; Felga G; Axelrod DA; Della Guardia B; Almeida MD; Rezende MB
    Am J Transplant; 2015 Mar; 15(3):668-77. PubMed ID: 25650130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.
    Kwong AJ; Lai JC; Dodge JL; Roberts JP
    Liver Transpl; 2015 Nov; 21(11):1403-9. PubMed ID: 26289624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
    Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
    Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short-Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change.
    Brondfield MN; Dodge JL; Hirose R; Heimbach J; Yao FY; Mehta N
    Liver Transpl; 2020 May; 26(5):662-672. PubMed ID: 31833634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list.
    Toso C; Majno P; Berney T; Morel P; Mentha G; Combescure C
    Transpl Int; 2014 Jul; 27(7):686-95. PubMed ID: 24649861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.
    Mehta N; Dodge JL; Hirose R; Roberts JP; Yao FY
    Liver Transpl; 2018 Oct; 24(10):1346-1356. PubMed ID: 30067889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States.
    Heimbach JK; Hirose R; Stock PG; Schladt DP; Xiong H; Liu J; Olthoff KM; Harper A; Snyder JJ; Israni AK; Kasiske BL; Kim WR
    Hepatology; 2015 May; 61(5):1643-50. PubMed ID: 25644186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.